Effect of sizofiran on regional lymph nodes in patients with head and neck cancer.
The immunomodulating effects of preoperative sizofiran (SPG) administration on regional lymph nodes were studied in patients with stage III or IV head and neck cancer, by comparing the immunofunction of peripheral blood. The regional lymph nodes were dissected surgically, and freshly obtained mononuclear cells were studied to investigate the interleukin 2 (IL-2) production, the LAK and NK activities, and the quantitative analysis of the surface phenotype of the mononuclear cells. The results indicated that SPG enhanced immunological activities in the regional lymph nodes, as shown by increased IL-2 production and cytotoxic activities of the effector cells (NK, LAK), and increased helper T lymphocytes (CD4+) in the tumor-uninvolved lymph nodes. The immunofunction following SPG administration was attenuated, but was still augmented in the regional lymph nodes with metastases. Therefore, SPG was found to be a biologic response modifier to enhance the immunofunctions of the regional lymph node in patients with head and neck cancer.
Kano
Y
Y
Department of Otorhinolaryngology, Teikyo University School of Medicine, Tokyo, Japan.
Kakuta
H
H
Hashimoto
J
J
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D008198:Lymph Nodes / Q000187:drug effects*; D012566:Sizofiran / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D000972:Antineoplastic Agents, Phytogenic; D007376:Interleukin-2; D012566:Sizofiran